

**SCIENTIFIC AND TECHNICAL COOPERATION**

**Health Research**

**Agreement Between the  
UNITED STATES OF AMERICA  
and UGANDA**

**Amends and Extends the Agreement of May 9, 2017**

Signed at Entebbe and Bethesda  
April 29, 2022 and May 11, 2022

Entered into force May 11, 2022  
Effective from May 9, 2022



NOTE BY THE DEPARTMENT OF STATE

Pursuant to Public Law 89—497, approved July 8, 1966  
(80 Stat. 271; 1 U.S.C. 113)—

“ . . .the Treaties and Other International Acts Series issued under the authority of the Secretary of State shall be competent evidence . . . of the treaties, international agreements other than treaties, and proclamations by the President of such treaties and international agreements other than treaties, as the case may be, therein contained, in all the courts of law and equity and of maritime jurisdiction, and in all the tribunals and public offices of the United States, and of the several States, without any further proof or authentication thereof.”

**AGREEMENT TO AMEND AND EXTEND**

**AGREEMENT BETWEEN**

**THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,  
NATIONAL INSTITUTES OF HEALTH,  
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**AND**

**THE UGANDA VIRUS RESEARCH INSTITUTE,  
MINISTRY OF HEALTH,  
REPUBLIC OF UGANDA**

**FOR**

**THE CONTINUATION OF COOPERATION ON AN INTERNATIONAL CENTER OF  
EXCELLENCE IN RESEARCH IN UGANDA**

The U.S. National Institute of Allergy and Infectious Diseases and the Ministry of Health of the Republic of Uganda (hereinafter “the Parties”),

Recognizing that the Agreement between the Parties for the Continuation of Cooperation on an International Center of Excellence in Research in Rakai, Uganda, signed May 9, 2017, (hereinafter “the Agreement”) will expire by its terms on May 9, 2022, and

Acting pursuant to Article 13 of the Agreement,

Have agreed as follows:

Article 1

In recognition of the recent expansion of the collaboration, to include a research program on emerging infectious diseases that will be based at the Uganda Virus Research Institute (UVRI) and involve field-based research throughout Uganda, the Title of the Agreement shall be amended to read “Agreement Between The National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services and The Uganda Virus Research Institute, Ministry of Health, Republic of Uganda for The Continuation of Cooperation on an International Center of Excellence in Research in Uganda”

Article 2

Article 3 (Facilities and Management), Section 3, bullet 2 shall be amended to read “Support to enhance laboratory capacity at the RHSP laboratory in Rakai and UVRI facilities identified for

joint collaborative activities, as determined through mutual discussion and research program needs;”

Article 3

All other terms and conditions of the 2017 Agreement shall remain the same. The Parties agree to recognize the continuation of the activities established by the 2017 Agreement and the modifications effected by this Agreement.

Article 4

The Agreement shall be extended for five years effective from May 9, 2022 and expiring May 9, 2027.

Article 5

This Agreement shall enter into force on the date of signature of both Parties.

IN WITNESS WHEREOF the undersigned, being duly authorized by their respective Governments, have signed this Agreement, which will enter into force on the date of signature of both Parties.

FOR THE NATIONAL INSTITUTE  
OF ALLERGY AND INFECTIOUS  
DISEASES, NATIONAL  
INSTITUTES OF HEALTH, U.S.  
DEPARTMENT OF HEALTH AND  
HUMAN SERVICES

*Anthony Fauci, MD*

Bethesda, MD

Place

05/11/2022  
Date

*[Handwritten Signature]*

FOR THE MINISTRY OF HEALTH  
OF THE REPUBLIC OF UGANDA

PONTIANO KALEERU - DIRECTOR  
UVR4

ENTEBBE  
Place

29<sup>th</sup> APRIL 2022  
Date